How New Treatments and Artificial Intelligence are Improving Multiple Aspects of Clinical Trials

As the head of clinical operations at Beat AML, Len Rosenberg, shared with the Applied Clinical Trials publication at the 2023 SCOPE Summit in Orlando, Florida, about the ways that he and his Beat AML team are tackling the operational obstacles that come with clinical trials, including background treatment dosages. With the support of The Leukemia & Lymphoma Society, BAML is now developing a less toxic regiment for a more promising treatment that will allow the patient to receive treatment in the privacy, safety, and comfort of their own home while breakthrough technologies allow for precision monitoring during the treatment process.

In addition to providing a more precise and adaptable treatment process for the patients, BAML is now partnering with Narrativa to utilize artificial intelligence (AI) machine learning (ML) algorithms to take safety datasets and automate them relative to how the trials are done. The Narrativa AI SaaS platform helps automate large portions of regulatory documentation, specifically Patient Safety Narratives, TLFs (Tables, Listings, and Figures) and Cross-Reporting, so that the BAML team improves the time and cost efficiency of the reporting process. This ultimately allocates more funding toward actual trials and finding more cures for patients.

Watch the full interview: